Abstract
(Abstracted from Gynecol Oncol 2021;163:220–228) Molecular tumor profiling with next-generation sequencing (NGS) has become increasingly used in the evaluation and treatment planning for primary and recurrent gynecologic cancer. This is driven by studies demonstrating that NGS-guided treatment results in longer time to treatment failure and overall survival while also being better tolerated than conventional chemotherapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
